🚀 VC round data is live in beta, check it out!
Nanjing King-Friend Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nanjing King-Friend and similar public comparables like Immunome, Mineralys Therapeutics, Disc Medicine, Jafron Biomedical and more.
Nanjing King-Friend Overview
About Nanjing King-Friend
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Founded
2000
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Nanjing King-Friend Financials
Nanjing King-Friend reported last 12-month revenue of $648M and EBITDA of $168M.
In the same LTM period, Nanjing King-Friend generated $260M in gross profit, $168M in EBITDA, and $121M in net income.
Revenue (LTM)
Nanjing King-Friend P&L
In the most recent fiscal year, Nanjing King-Friend reported revenue of $571M and EBITDA of $181M.
Nanjing King-Friend expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $648M | XXX | $571M | XXX | XXX | XXX |
| Gross Profit | $260M | XXX | $247M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $168M | XXX | $181M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 32% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $121M | XXX | $120M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 21% | XXX | XXX | XXX |
| Net Debt | — | — | $150M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nanjing King-Friend Stock Performance
Nanjing King-Friend has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Nanjing King-Friend's stock price is $1.43.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.2% | XXX | XXX | XXX | $0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNanjing King-Friend Valuation Multiples
Nanjing King-Friend trades at 3.5x EV/Revenue multiple, and 13.5x EV/EBITDA.
EV / Revenue (LTM)
Nanjing King-Friend Financial Valuation Multiples
As of March 21, 2026, Nanjing King-Friend has market cap of $2B and EV of $2B.
Equity research analysts estimate Nanjing King-Friend's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nanjing King-Friend has a P/E ratio of 19.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 3.5x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.5x | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBIT | 16.2x | XXX | 17.0x | XXX | XXX | XXX |
| EV/Gross Profit | 8.7x | XXX | 9.2x | XXX | XXX | XXX |
| P/E | 19.1x | XXX | 19.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 15.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nanjing King-Friend Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nanjing King-Friend Margins & Growth Rates
Nanjing King-Friend's revenue in the last 12 month grew by 19%.
Nanjing King-Friend's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nanjing King-Friend's rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Nanjing King-Friend Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 30% | XXX | (13%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 9% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nanjing King-Friend Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Immunome | XXX | XXX | XXX | XXX | XXX | XXX |
| Mineralys Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Disc Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Jafron Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Hepalink | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nanjing King-Friend M&A Activity
Nanjing King-Friend acquired XXX companies to date.
Last acquisition by Nanjing King-Friend was on XXXXXXXX, XXXXX. Nanjing King-Friend acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nanjing King-Friend
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNanjing King-Friend Investment Activity
Nanjing King-Friend invested in XXX companies to date.
Nanjing King-Friend made its latest investment on XXXXXXXX, XXXXX. Nanjing King-Friend invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nanjing King-Friend
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nanjing King-Friend
| When was Nanjing King-Friend founded? | Nanjing King-Friend was founded in 2000. |
| Where is Nanjing King-Friend headquartered? | Nanjing King-Friend is headquartered in China. |
| Is Nanjing King-Friend publicly listed? | Yes, Nanjing King-Friend is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Nanjing King-Friend? | Nanjing King-Friend trades under 603707 ticker. |
| When did Nanjing King-Friend go public? | Nanjing King-Friend went public in 2017. |
| Who are competitors of Nanjing King-Friend? | Nanjing King-Friend main competitors are Immunome, Mineralys Therapeutics, Disc Medicine, Jafron Biomedical. |
| What is the current market cap of Nanjing King-Friend? | Nanjing King-Friend's current market cap is $2B. |
| What is the current revenue of Nanjing King-Friend? | Nanjing King-Friend's last 12 months revenue is $648M. |
| What is the current revenue growth of Nanjing King-Friend? | Nanjing King-Friend revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of Nanjing King-Friend? | Current revenue multiple of Nanjing King-Friend is 3.5x. |
| Is Nanjing King-Friend profitable? | Yes, Nanjing King-Friend is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nanjing King-Friend? | Nanjing King-Friend's last 12 months EBITDA is $168M. |
| What is Nanjing King-Friend's EBITDA margin? | Nanjing King-Friend's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Nanjing King-Friend? | Current EBITDA multiple of Nanjing King-Friend is 13.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.